Hologic’s first quarter saw results broadly in line with Wall Street expectations, yet the company’s shares declined after the report as investors digested softer demand in select segments and international pressures. Management pointed to strong recurring revenue growth—especially in breast health services—as a stabilizing factor, while acknowledging that tariff costs and funding cuts in Africa weighed on diagnostic sales. CEO Steve MacMillan highlighted, “our Diagnostics business continued to grow nicely, despite steep declines in our Africa business following funding cuts,” and noted that recurring revenue now makes up a substantial portion of total sales.

Is now the time to buy HOLX? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Hologic’s Q1 Earnings Call

• Patrick Donnelly (Citi) asked about the extent of supplier price increases from tariffs and mitigation strategies. CEO Steve MacMillan responded that the company expects offsets but is not seeing major supplier discussions yet.
• Tejas Savant (Morgan Stanley) questioned whether the guidance haircut reflected more than just China and tariffs. CFO Karleen Oberton clarified that increased weakness in Africa and China were the primary factors.
• Jack Meehan (Nephron Research) inquired about the rationale for lowering China expectations and the outlook for utilization trends. MacMillan said derisking China was prudent and described a steadier utilization environment.
• Puneet Souda (Leerink Partners) asked about supply chain changes in response to tariffs and capital spending pressure for new gantries. MacMillan said the current manufacturing footprint is well-positioned, and hospital budgets are not a major barrier for planned equipment upgrades.
• Casey Woodring (J.P. Morgan) probed the sustainability of service revenue growth in breast health. Oberton cited increased attach rates and a growing installed base as key drivers, with expectations for continued outperformance.

Catalysts in Upcoming Quarters

In the coming quarters, our analyst team will be watching (1) the pace and effectiveness of breast health sales force changes and gantry replacement initiatives, (2) the company’s ability to mitigate the financial impact of tariffs and navigate international market volatility, and (3) the sustained growth trajectory of molecular diagnostics and service revenue. Progress on integrating recent acquisitions and successful new product launches will also be critical signposts.

Hologic currently trades at $64.27, up from $57.25 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.